183 related articles for article (PubMed ID: 30697576)
1. Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis.
Ciardi MR; Iannetta M; Zingaropoli MA; Salpini R; Aragri M; Annecca R; Pontecorvo S; Altieri M; Russo G; Svicher V; Mastroianni CM; Vullo V
Open Forum Infect Dis; 2019 Jan; 6(1):ofy356. PubMed ID: 30697576
[TBL] [Abstract][Full Text] [Related]
2. Risk of hepatitis B virus reactivation in people with multiple sclerosis treated with ocrelizumab: an observational study from Turkey.
Çelik M; Baba C; Irmak Ç; Özakbaş S; Avkan-Oğuz V
J Neurol; 2024 Apr; ():. PubMed ID: 38578494
[TBL] [Abstract][Full Text] [Related]
3. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
[TBL] [Abstract][Full Text] [Related]
4. Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.
Buonomo AR; Viceconte G; Calabrese M; De Luca G; Tomassini V; Cavalla P; Maniscalco GT; Ferraro D; Nociti V; Radaelli M; Buscarinu MC; Paolicelli D; Gajofatto A; Annovazzi P; Pinardi F; Di Filippo M; Cordioli C; Zappulo E; Scotto R; Gentile I; Spiezia AL; Petruzzo M; De Angelis M; Brescia Morra V; Solaro C; Gasperini C; Cocco E; Moccia M; Lanzillo R;
J Neurol; 2022 Jun; 269(6):3301-3307. PubMed ID: 35165767
[TBL] [Abstract][Full Text] [Related]
5. OCRELIZUMAB THERAPY IN PATIENTS WITH ANTI-HBC ANTIBODIES - A PRELIMINARY STUDY.
Niedziela N; Zimnol A; Lubczyński M; Szymbara P; Kubicka-Bączyk K; Jaroszewicz J; Adamczyk-Sowa M
Pol Merkur Lekarski; 2023; 51(3):189-193. PubMed ID: 37589101
[TBL] [Abstract][Full Text] [Related]
6. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma.
Matsue K; Kimura S; Takanashi Y; Iwama K; Fujiwara H; Yamakura M; Takeuchi M
Cancer; 2010 Oct; 116(20):4769-76. PubMed ID: 20597091
[TBL] [Abstract][Full Text] [Related]
7. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
Niitsu N; Hagiwara Y; Tanae K; Kohri M; Takahashi N
J Clin Oncol; 2010 Dec; 28(34):5097-100. PubMed ID: 20837949
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study.
Seto WK; Chan TS; Hwang YY; Wong DK; Fung J; Liu KS; Gill H; Lam YF; Lie AK; Lai CL; Kwong YL; Yuen MF
J Clin Oncol; 2014 Nov; 32(33):3736-43. PubMed ID: 25287829
[TBL] [Abstract][Full Text] [Related]
9. Successful switch to ofatumumab after liver injury associated with ocrelizumab treatment in multiple sclerosis: a case report.
Mariottini A; Barilaro A; Lotti A; Marra F; Massacesi L
Front Neurol; 2024; 15():1363493. PubMed ID: 38487332
[TBL] [Abstract][Full Text] [Related]
10. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
[TBL] [Abstract][Full Text] [Related]
11. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection.
Yang HC; Tsou HH; Pei SN; Chang CS; Chen JH; Yao M; Lin SJ; Lin J; Yuan Q; Xia N; Liu TW; Chen PJ; Cheng AL; Hsu C;
J Hepatol; 2018 Aug; 69(2):286-292. PubMed ID: 29551710
[TBL] [Abstract][Full Text] [Related]
12. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
[TBL] [Abstract][Full Text] [Related]
13. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
[TBL] [Abstract][Full Text] [Related]
14. Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.
Viganò M; Mangia G; Lampertico P
Expert Opin Biol Ther; 2014 Jul; 14(7):1019-31. PubMed ID: 24909454
[TBL] [Abstract][Full Text] [Related]
15. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
Chen FW; Coyle L; Jones BE; Pattullo V
Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
[TBL] [Abstract][Full Text] [Related]
16. Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy.
Kusumoto S; Tobinai K
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):576-83. PubMed ID: 25696914
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
19. The difficulties of managing severe hepatitis B virus reactivation.
Roche B; Samuel D
Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Accelerated Vaccination against Hbv to Achieve Antibody formation in Multiple Sclerosis Patients Receiving Anti-Cd20 Therapy.
Koc ER; Turan OF; Saridas F; Menguc B; Minaz SN; Ozkaya G
Ann Indian Acad Neurol; 2023; 26(5):697-701. PubMed ID: 38022448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
